HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.

AbstractBACKGROUND AND OBJECTIVE:
Recent research suggests that cannabinoid receptor CB1 antagonists can affect appetite and body weight gain, although their influence on other parameters related to metabolic syndrome is not well documented. The present study was designed to assess the effects of chronic treatment with the CB1 receptor inverse agonist AM 251 (3 mg/kg for 3 weeks) in obese and lean Zucker rats on parameters related to metabolic syndrome.
MATERIALS AND METHODS:
Four groups of rats were used: lean Zucker rats, untreated obese Zucker rats, AM 251-treated obese Zucker rats and a pair-fed obese Zucker rat experimental group which received the same amount of food as that consumed by the animals treated with AM251. Food intake, body weight gain, energy expenditure, plasma biochemical parameters, leptin, insulin and hepatic status markers were analysed.
RESULTS:
Daily injection of AM 251 in obese Zucker rats produced a marked and sustained decrease in daily food intake and body weight and a considerable increase in energy expenditure in comparison with untreated obese Zucker rats. AM 251 administration to obese rats significantly reduced plasma levels of glucose, leptin, AST, ALT, Gamma GT, total bilirubin and LDL cholesterol whereas HDL cholesterol plasma levels increased. The results also showed a decrease in liver/weight body ratio and total fat content in the liver. The main effects of AM251 (3 mg/kg) found in this study were not observed in pair-fed obese animals, highlighting the additional beneficial effects of treatment with AM 251. The results obtained in obese rats can be interpreted as a decrease in leptin and insulin resistance, thereby improving glucose and lipid metabolism, alleviating the steatosis present in the metabolic syndrome and thus favourably modifying plasma levels of hepatic biomarkers.
CONCLUSION:
Our results indicate that the cannabinoid CB1 inverse agonist AM 251 represents a promising therapeutic strategy for the treatment of obesity and metabolic syndrome.
AuthorsIkram Merroun, Cristina Sánchez-González, Rosario Martínez, Carlos López-Chaves, Jesús M Porres, Pilar Aranda, Juan Llopis, Milagros Galisteo, Antonio Zarzuelo, Mohammed Errami, María López-Jurado
JournalMetabolism: clinical and experimental (Metabolism) Vol. 62 Issue 11 Pg. 1641-50 (Nov 2013) ISSN: 1532-8600 [Electronic] United States
PMID23932644 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013.
Chemical References
  • Biomarkers
  • Cannabinoid Receptor Antagonists
  • Insulin
  • Leptin
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • AM 251
Topics
  • Animals
  • Biomarkers (blood)
  • Cannabinoid Receptor Antagonists (pharmacology)
  • Eating (drug effects)
  • Energy Metabolism (drug effects)
  • Fatty Liver (metabolism, prevention & control)
  • Insulin (blood)
  • Insulin Resistance
  • Leptin (blood)
  • Lipid Metabolism
  • Liver (drug effects, metabolism)
  • Male
  • Metabolic Syndrome (blood, drug therapy, metabolism, physiopathology)
  • Obesity (blood, drug therapy, metabolism, physiopathology)
  • Piperidines (pharmacology)
  • Pyrazoles (pharmacology)
  • Rats
  • Rats, Zucker
  • Receptor, Cannabinoid, CB1 (antagonists & inhibitors, metabolism)
  • Weight Gain (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: